Status:
COMPLETED
Somatuline Predictive Factors in Acromegaly and NET
Lead Sponsor:
Ipsen
Conditions:
Acromegaly
Neuroendocrine Tumours
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the study is to identify predictive factors for the response to Lanreotide treatment in Acromegaly as well as in Neuroendocrine Tumours.
Eligibility Criteria
Inclusion
- Written informed consent (also mandatory in case of retrospective documentation of subject data)
- Diagnosis of acromegaly or NET with the intention to be treated with ATG or already on treatment with ATG
Exclusion
- The subject has already been included in this study
- Participation in an interventional trial
Key Trial Info
Start Date :
June 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2017
Estimated Enrollment :
156 Patients enrolled
Trial Details
Trial ID
NCT01840449
Start Date
June 1 2012
End Date
May 1 2017
Last Update
January 14 2019
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Vienna
Vienna, Austria
2
ENDOC
Hamburg, Germany
3
University Hospital Basel
Basel, Switzerland